I hope you're shorting the stock to really put it to ISIS. I also hope you are the one who sold Apple to buy more vicl......one almost gets nauseated when you think if that trade went down. I can hardly wait till you say sell this POS when it is going for over $120 and you are talking about how good vicl is going to do while it is less and a buck fifty. t
You are retarded and you are feeling sorry for everyone else. That shows that you do have some feelings and generosity while you are being fleeced on your vicl stock. Wish you well and hope you don't become homeless. t
Next vicl challenge. Will vicl break a buck 38 before ISIS breaks $42?? Remember we keep on moving up ISIS target price and keep vicl the same at a buck 38. That's called a handicap in bowling. I except however that vicl will get bowled over. A worthless stock that will fall to the likes of KITE. t
ISIS in one day is up double the total price of vicl. A losing cause on their part. KITE is the real vaccine player with modern technology that vicl will never have. My dog is safe from dog mouth melanoma though thanks to vicl. t
KITE is the vaccine company to hold. Look at them today. t
By sticking with vicl your kids are going to have to support you. Just keep talking and everyone will keep watching. t
Bad news coming for vicl, and for ISIS shorts. Whoever of your friends said that they sold Apple and bought vicl? That has to be an outright lie, or the dumbest trade in stock history. If I had Apple stock I wouldn't sell it to buy more ISIS when both companies have huge potential, why not keep your diversity. But to sell vicl and buy Apple......that's a Saturday Night thing!!! t
Macro, could you please give me a price quote on vicl for today. My computer is locked out from their website and I wanted to know how they did as compared to ISIS? TIA, t
I'd abandon AEGR really, they are a one trick pony, and really mipo will slowly erode some of their share and they will struggle. It isn't a matter of them getting patients, it is how many patients are there out there and time is against them with competitors. I'd bug out Ranger, or at least reduce my exposure. From old rival to old rival it isn't the best biotech out there. But good luck if you do hold. t
Cut Arthur a break too Ranger, you'd like him. And really Mipo does work, an article today noting that it may be the drug of choice in patients with HoF with coagulopathy. Both companies may eventually split that market, but you'd honestly do better over here with ISIS long term. Close to hitting it big with their SMN drug, they also have unbelievable drugs coming after that including their ApoC III inhibitor, their Factor XI inhibitor, their DM Type 2 drug portfolio, and a host of others. They also are the leader IMO for Huntington's disease, ALS, Retinitis Pigmentosa, Usher's Syndrome.....the more you look the more you will see that they have had 12 to 14 years of uninterrupted research with no lay-offs of threats to lay-offs unlike a host of other RNAi companies. Really glad you're here, and also that you call a spade a spade in regards to vicl. t
Hey halt the ranger guy and you're not half bad in some regards. SRPT isn't a bad stock and will eventually prevail. They aren't an ISIS but they aren't bad. You should look into ISIS a little bit and not be bitter about AEGR.....and I'm not saying that to be a smarter-pants. Really, if you look into it you'll find that they are really the leader in ANS technology and can do what no other RNA company can do. RNAi companies do have some pretty good products, but they are limited to the liver. With ligand technology ISIS will be able to in some cases uses meds that are 600 fold more powerful than before, and thus really lower the dose. With ligands and drugs that aren't limited to the liver they can deliver to almost any part of the body. Really take a look at them, you're kind of an old acquaintance so I'd like to welcome you to the ISIS board here. t
Also, the initial data I saw for the arthritis drug looked very good. Was I mistaken? t
Constitutive AKT activation in follicular lymphoma Full Text
BMC Cancer, 08/20/2014 Clinical Article
Yahiaoui OI, et al. – The phosphoinositide 3– kinase (PI3K) pathway is involved in the growth of various human cancers, including lymphoid malignancies. This resear5ch aimed to find out its role in the pathogenesis of follicular lymphoma (FL). The data suggest that the PI3K/AKT signaling pathway could be activated in a subset of FL cases, due to either AKT phosphorylation or PTEN downregulation, in the absence of PIK3CA mutations.
•To clarify this point, biopsy tissue samples from 38 human FL cases were investigated for PIK3CA somatic mutations in exon 9 and 20 using direct sequencing.
• The same samples were analyzed using western blotting and immunohistochemistry to detect expression of AKT, phosphorylated AKT (pAKT), and PTEN proteins.
• Two cases of benign lymphadenitis were used as controls.
• AKT expression was present in all FL and lymphadenitis cases.
•14/38 (37%) FL and 2/2 lymphadenitis cases expressed pAKT.
•9/38 (24%) FL samples showed high level of pAKT, whereas 5/38 (13%) FL cases and 2/2 benign lymphadenitis samples expressed low level of pAKT.
• PTEN expression was observed in 30/38 (79%) FL and 2/2 benign lymphadenitis cases, whereas 8/38 (21%) FL cases showed loss of PTEN expression.
•3 cases with positive pAKT did not express PTEN. PIK3CA mutations were not detected in any sample.
Kite Pharma resumed with a Buy at Stifel; tgt $31 (22.95)
Stifel resumes coverage of KITE with a Buy and sets target price at $31. Kite is currently at the front of a group of companies looking to commercialize Chimeric Antigen Receptor T-cell (CAR-T) therapies for cancer. To date, this approach has shown remarkable efficacy and has attracted the attention of oncologists and investors alike. There are several companies on Kite's tail, but firm believes first mover advantage gives Kite's seasoned mgmt team a good chance to be one of the big commercial winners in this new branch of immune oncology.
Where is the next wonder drug coming from with vicl??? What is it??? Does it vaccinate your dog from fleas, ticks, and black flies??? t
Within the period of one year vicl was three times what it is today. ISIS was about 2/3 of what it Is today. I would learn to speak Russian and apply for a job with Putin for Russian public relations with your constant slant on reality. Soon though you will all be gone to that big vaccine BK in the sky. The sooner the better. You can pick out a new challenger then. t